76153-06-5

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs with specific therapeutic properties.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE serves as a versatile building block for the creation of a wide range of organic compounds, contributing to the advancement of chemical research and product development.
Used in Dyes and Pigments Production:
5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE is utilized in the production of dyes and pigments due to its chemical structure, which imparts color and stability to these products.
Used in Research and Laboratory Settings:
As a building block for specialized molecules, 5-BROMO-3-METHYL-BENZENE-1,2-DIAMINE is used in research and laboratory settings to create molecules with specific properties and functions, contributing to scientific discovery and innovation.

InChI:InChI=1/C7H9BrN2/c1-4-2-5(8)3-6(9)7(4)10/h2-3H,9-10H2,1H3

Upstream product

• 77811-44-0 4-bromo-2-methyl-6-nitroaniline 
• 120-66-1 N-(2-methylphenyl)acetamide 
• 24106-05-6 4'-bromo-2'-methylacetanilide 
• 95-53-4 o-toluidine 
• 1266383-33-8 C₇H₇BrN₂O₂ 
• 570-24-1 2-Methyl-6-nitroaniline 

Downstream Products

• 255064-10-9 6-bromo-4-methyl-1H-benzo[d]imidazole 
• 93587-18-9 3-(6-Bromo-4-methyl-1H-benzoimidazol-2-yl)-pyridin-2-ylamine 
• 77811-41-7 6-bromo-2-mercapto-4-methylbenzimidazole 
• 187479-57-8 7‐bromo‐5‐methyl‐1,4‐dihydroquinoxaline‐2,3‐dione 
• 468741-06-2 6-bromo-2-(4-iodo-2-methoxy-pyridin-3-yl)-4-methyl-1H-benzimidazole 
• 808745-20-2 6-bromo-2-ethoxy-4-methyl-1H-benzimidazole 
• 941696-21-5 ethyl (2-amino-5-bromo-3-methylphenyl)carbamate 
• 1156741-11-5 C₁₀H₁₃BrN₂O₂ 
• 255064-10-9 5-bromo-7-methyl-1H-benzo[d]imidazole 
• 1162695-97-7 C₁₆H₁₃BrN₂O₂ 
• 1259015-07-0 3-bromo-1-methylphenazine 
• 532934-95-5 7‐bromo‐5‐methylquinoxaline 

Relevant academic research and scientific papers

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS

The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol as defined in the specification, or a salt thereof.

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as m PGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

The development of benzimidazoles as selective rho kinase inhibitors

Rho Kinase (ROCK) is a serine/threonine kinase whose inhibition could prove beneficial in numerous therapeutic areas. We have developed a promising class of ATP-competitive inhibitors based upon a benzimidazole scaffold, which show excellent potency toward ROCK (IC50 10 nM). This report details the optimization of selectivity for ROCK over other related kinases such as Protein kinase A (PKA).

Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile

A series of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) were examined in which the pendant imidazole moiety was replaced to improve selectivity for IGF-1R inhibition over cytochrome P450 (CYP). Synthesis and SAR of these compounds is presented.

Benzimidazole C-2 heterocycles as kinase inhibitors

Benzimidazole derivatives having the general formula I are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.

Novel tyrosine kinase inhibitors

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.

BENZIMIDAZOLE COMPOUNDS

The present invention provides novel benzimidazole compounds of the formula (I): wherein each symbol is as defined in the specification, salts thereof and prodrugs thereof, which are useful in treating, for example, the diseases curable through decrease in blood sugar level.

The nitration of 8-methylquinoxalines in mixed acid

8-Methylquinoxalines are nitrated surprisingly efficiently at C-5 following a simple nitration protocol with mixed acid at 40-50°C. The implications of halogen functionalisation at C-6 and modification of the mixed acid conditions on the relative rates of conversion and process safety are discussed. Competing side reactions for 6-halo-8-methylquinoxalines involve hydrolysis at C-6 and halogenation at C-7 or C-5.

2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives

PCT No. PCT/EP96/03644 Sec. 371 Date Feb. 27, 1998 Sec. 102(e) Date Feb. 27, 1998 PCT Filed Aug. 19, 1996 PCT Pub. No. WO97/08155 PCT Pub. Date Mar. 6, 19972,3-Dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives of formula (I), wherein one of the radicals R1, and R2 is a group R5 and the other is a group of formula -CH(R6)-alk-R7 (Ia), -alk-CH(R6-R7 (Ib), -alk-N(R8)-X-R7 (Ic), -alk-N+(R8)(R9)-X-R7A- (Id), -alk-O-X-R7 (Ie) or -alk-S-X-R7 (If), R3, R4 and R5 are each independently of the others hydrogen, lower alkyl, halogen, trifluoromethyl, cyano or nitro, R6 is unsubstituted or lower alkylated and/or lower alkanoylated amino, R7 is hydrogen; an aliphatic, cycloaliphatic or heterocycloaliphatic radical; cyano; acyl derived from carbonic acid or from a semiester or semiamide of carbonic acid, from sulfuric acid or from an aliphatic or aromatic sulfonic acid or from phosphoric acid or from a phosphonic acid ester; amino that is unsubtituted or aliphatically or araliphatically substituted and/or substituted by aliphatic, araliphatic or aromatic acyl; or an aromatic or heteroaromatic radical, R8 is hydrogen; an aliphatic or araliphatic radical; or acyl derived from an aliphatic or araliphatic carboxylic acid or from an aliphatic or araliphatic semiester of carbonic acid, or R7 and R8, together with X and the nitrogen atom bonding R8 and X, form an unsubstitued or substituted mono- or di-azaxycloalkyl, azoxacycloalkyl, azathiacycloalkyl or optionally oxidised thiacycloalkyl radical bonded via a nitrogen atom, or an unsubstituted or substituted, optionally partially hxdrogenated aryl or heteroaryl radical, R9 is an aliphatic or araliphatic radical, or R7, R8 and R9 together with X and the nitrogen atom bonding R8, R9 and X, form an unsubstituted or substituted quaternary heteroaryl radical bonded via the quaternary nitrogen atom, with A- being the anion of a protonic acid, alk is lower alkylene, and X (unless, together with R7 and R8 and the nitrogen atom bonding R8 and X or together with the nitrogen atom bonding R8, R9 and X, it forms part of one of the mentioned ring systems) is a divalent aliphatic, cycloaliphatic or araliphatic radical or a direct bond, and the pharmaceutically acceptable salts thereof can be used in the preparation of a medicament for the treatment of pathological conditions that are responsive to blocking of AMPA, kainate and/or glycine binding sites of the NMDA receptor.